Participant List

Eleni Anagnostiadis  
Director, Patient Affairs and Stakeholder Engagement, U.S. Food and Drug Administration

Jinsy Andrews  
Associate Professor of Neurology, Director of Neuromuscular Clinical Trials, Columbia University

Nazneen Barwick  
Director, Clinical Development, GlaxoSmithKline

Eric Bastings  
Deputy Director, Office of Neuroscience; Acting Director, Division of Neurology 1, Office of Neuroscience, U.S. Food and Drug Administration

Emily Baxi  
Executive Director, The Robert Packard Center for ALS Research at Johns Hopkins

Richard Bedlack  
Director, Duke ALS Clinic, Professor of Neurology, Duke University

Michael Benatar  
Professor of Neurology, Walter Bradley Chair in ALS Research, University of Miami

Visar Berisha  
Chief Analytics Officer, Co-Founder, Aural Analytics

Kristina Bowyer  
Vice President, Patient Centric Drug Development, Ionis Pharmaceuticals

Beth Boyer  
Research Associate, Duke-Margolis Center for Health Policy

Shawn Brooks  
Health Communications Specialist, Patient Affairs and Stakeholder Engagement, U.S. Food and Drug Administration

Wilson Bryan  
Director, Office of Cellular, Tissue, and Gene Therapies, U.S. Food and Drug Administration

Matthew Buck  
Vice President, Regulatory Affairs, Ionis Pharmaceuticals

Teresa Buracchio  
Deputy Director, Division of Neurology 1, U.S. Food and Drug Administration

Michelle Campbell  
Senior Clinical Analyst for Stakeholder Engagement and Clinical Outcomes, Office of Neuroscience, U.S. Food and Drug Administration

Danielle Carnival  
Chief Executive Officer, I AM ALS

Patrizia Cavazzoni  
Acting Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lakeecha Chenjo  
Program Analyst, Stakeholder Engagement, Office of External Affairs, U.S. Food and Drug Administration
Susan Chittooran  
Patient Engagement Project Manager, Office of Patient Affairs, U.S. Food and Drug Administration

Alecia Clary  
Associate Director for Research, Reagan-Udall Foundation for the FDA

Joshua Cohen  
Chief Executive Officer, Co-Founder, Amylyx

Mildred Cooper  
U.S. Food and Drug Administration

Rebecca Crean  
Director, Clinical Development, Ionis Pharmaceuticals

Dayle Cristinizio  
Director, Stakeholder Engagement, Office of External Affairs, U.S. Food and Drug Administration

Merit Cudkowicz  
Chief of the Massachusetts General Hospital Neurology Service, Director, Sean M. Healey & AMG Center at MGH

Kuldip Dave  
Vice President of Research, The ALS Association

Billy Dunn  
Director, Office of Neuroscience, U.S. Food and Drug Administration

Clare Durrett  
Strategic Advisor—Advocacy, Legislation, and Communications, Team Gleason

Noam Epstein  
Neuroscience Discovery Medicine Physician, GlaxoSmithKline

Meredith Estess  
President, Co-Founder, Project ALS

Valerie Estess  
Director of Research, Co-Founder, Project ALS

Toby Ferguson  
Head of the Neuromuscular Development Unit, Biogen

James Flahive  
Senior Advisor, Office of the Commissioner, U.S. Food and Drug Administration

Erin Fleming  
Director of Research Operations, Project ALS

Lois Freed  
Division Director, Division of Pharmacology/Toxicology, Office of Neuroscience, U.S. Food and Drug Administration

Emily Freilich  
Team Leader, Division of Neurology 1, U.S. Food and Drug Administration

Andrea Furia-Helms  
Director, Patient Affairs, U.S. Food and Drug Administration

William Garofano  
Clinical Trial Manager, AZTherapies

Robert L. Glanzman  
Chief Medical Officer, Clene Nanomedicine, Inc.

John Goodrich  
Health Program Coordinator, Stakeholder Engagement, Office of External Affairs, U.S. Food and Drug Administration

Philip Green  
ALS Research Ambassador

Amelie Gubitz  
Program Director, Division of Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health
Ron Hoffman
Executive Director, Founder Compassionate Care ALS

Jonathan Hollander
Program Director, Genes, Environment and Health Branch, National Institute of Environmental Health Sciences, National Institutes of Health

Megan Howard
Congressional Affairs Specialist, Office of Legislation, U.S. Food and Drug Administration

Nicholas Hulbig
Manager, Clinical Trial, AZTherapies

Sophia Jeon
Health Science Policy Analyst, Office of Science and Policy Planning, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Andreas Kalmes
Director, Clinical Research, Revalesio

Sadhna Khatri
Associate Director of Operations, Professional Affairs and Stakeholder Engagement, U.S. Food and Drug Administration

Justin Klee
Chief Executive Officer, Co-Founder, Amylyx

Justin Kwan
Director, Neurodisorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Jane Larkindale
Executive Director, Duchenne Regulatory Sciences Consortium, Rare Disease Cures Accelerator-Data and Analytics Platform, Critical Path Institute

Diane Maloney
Associate Director for Policy, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Peter Marks
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Mark McClellan
Director, Duke-Margolis Center for Health Policy

Paul Mehta
Principal Investigator, National ALS Registry, Centers for Disease Control and Prevention

Paul Melmeyer
Director, Regulatory Affairs, Muscular Dystrophy Association

Carolina Mendoza-Puccini
Program Officer, Division of Clinical Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Sandy Morris
ALS Patient Advocate, I AM ALS

Lindsey O’Keefe
Press Officer, Office of Media Affairs, U.S. Food and Drug Administration

Sabrina Paganoni
Co-Director, Massachusetts General Hospital Neurological Clinical Research Institute

Erin and Mick Palmesano
ALS Patient Advocates

Valerie J. Parker
Policy Analyst, Duke-Margolis Center for Health Policy

Melanie Quintana
Director, Senior Statistical Scientist, Berry Consultants
Irfan Qureshi  
Vice President, Neurology, Biohaven Pharmaceuticals

Manish Raisinghani  
Chief Executive Officer, Target ALS

Morgan Romine  
Chief of Staff, Duke-Margolis Center for Health Policy

Anne Rowzee  
Associate Director for Policy, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration

Sarah M. Sheehan  
Managing Associate, Duke-Margolis Center for Health Policy

Jeremy Shefner  
Kemper and Ethel Marley Professor, Chair of Neurology, Senior Vice President, Barrow Neurological Institute

Alexander Sherman  
Director, Center for Innovation and Bioinformatics, Massachusetts General Hospital Neurological Clinical Research Institute

Shannon K. Shryne  
President and Co-Founder, Augie’s Quest

Wendy Slavit  
Health Program Coordinator, Patient Affairs, U.S. Food and Drug Administration

LaShawn Sykes  
Public Health Analyst, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Neil Thakur  
Chief Mission Officer, The ALS Association

Julia (Julie) Tierney  
Chief of Staff, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Matt Toole  
Patient Advocate

Bryan Traynor  
Neurologist & Senior Investigator, Neuromuscular Disease Research Section, National Institute on Aging, National Institutes of Health

Julienne Vaillancourt  
Rare Disease Liason, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Fernando Vieira  
Chief Scientific Officer, ALS Therapy Development Institute

Richard White  
Policy Analyst, National Organization for Rare Diseases

Lori Wiggins  
Deputy Director, Division of Orthopedic Devices, U.S. Food and Drug Administration

Lei Xu  
Chief of General Medicine Branch 2, Division of Clinical Evaluation and Pharmacology/Toxicology, U.S. Food and Drug Administration

Jill Yersak  
Senior Director, Mission and Strategy, The ALS Association